TXMDHealthcare · Drug Manufacturers - Specialty & GenericTXMD Stock Forecast: TherapeuticsMD, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 8 Aug 2026 — inside the top quartile.
TXMD stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores TherapeuticsMD, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (87): Smaller than most of the companies we track.
Revisions (25): Analysts have, on balance, been cutting their forecasts.
The rank is the raw material. Whether the rules would actually own TherapeuticsMD, Inc. — and when they’d sell — is the membership.
TXMD stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TXMD, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Of the 20 most recent actions, 2 moved their price target up and 6 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 17 Aug 2023 | Cantor Fitzgerald | Reiterates | Neutral | $5.00 |
| 17 Aug 2023 | Cantor Fitzgerald | Reiterates | Neutral | — |
| 11 Jan 2023 | Cantor Fitzgerald | Reinstates | Neutral | $5.00 |
| 13 July 2022 | Cantor Fitzgerald | Reiterates | Neutral | — |
| 7 June 2022 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 6 May 2022 | Cantor Fitzgerald | Downgrade | Neutral | $5.00 → $1.00 |
| 11 Mar 2022 | HC Wainwright & Co. | Maintains | Buy | $3.00 → $2.50 |
| 12 Nov 2021 | HC Wainwright & Co. | Maintains | Buy | $4.00 → $3.00 |
| 7 Aug 2020 | Jefferies | Downgrade | Underperform | $1.25 → $1.20 |
| 19 May 2020 | JP Morgan | Downgrade | Neutral | — |
| 7 May 2020 | H.C. Wainwright | Reiterates | Buy | — |
| 7 May 2020 | HC Wainwright & Co. | Reiterates | Buy | $6.00 → $5.00 |
| 16 Apr 2020 | Stifel | Maintains | Buy | $14 → $15 |
| 21 Feb 2020 | H.C. Wainwright | Maintains | Buy | — |
| 21 Feb 2020 | HC Wainwright & Co. | Maintains | Buy | $7.00 → $6.00 |
| 14 Aug 2018 | Cantor Fitzgerald | Maintains | Overweight | $26 → $27 |
| 15 June 2018 | JP Morgan | Initiates | Overweight | — |
| 8 Sept 2017 | Morgan Stanley | Initiates | Equal-Weight | — |
| 21 July 2017 | Deutsche Bank | Initiates | Buy | — |
| 11 July 2017 | Oppenheimer | Upgrade | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TXMD analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
TherapeuticsMD, Inc. (TXMD) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 207.0×
- Price / sales
- 7.1×
- Price / book
- 0.9×
- EV / EBITDA
- −15.2×
Cheaper than 3% of US stocks
Cheaper than 19% of US stocks
Cheaper than 76% of US stocks
Cheaper than 87% of US stocks
- Revenue growth (YoY)
- 84.2%
- Earnings growth (YoY)
- 84.2%
- Gross margin
- —
- Operating margin
- −28.5%
- Net margin
- 5.3%
Higher than 92% of US stocks
Higher than 83% of US stocks
Higher than 20% of US stocks
Higher than 61% of US stocks
- Return on equity
- 0.3%
- Return on assets
- −3.0%
- Dividend yield
- —
Higher than 44% of US stocks
Higher than 35% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
TXMD vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TXMD appears on the weeks it earns a place.
Frequently asked questions about TXMD stock
Is TXMD stock a buy right now?
Of the 9 analysts covering TherapeuticsMD, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TherapeuticsMD, Inc. 79 out of 100 across roughly 4,600 US stocks as at 8 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TXMD?
As at 8 Aug 2026, TherapeuticsMD, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (87 of 100).
What is the TXMD stock forecast for 2030?
No analyst covering TherapeuticsMD, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TXMD are extrapolating price history, which says nothing about the business.
How has TXMD stock performed over the past year?
TherapeuticsMD, Inc. returned +88.2% over the 12 months to 7 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does TherapeuticsMD, Inc. do?
TherapeuticsMD, Inc. is a specialty pharmaceutical and royalty company focused on women’s health in the United States and internationally.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is a specialty pharmaceutical and royalty company focused on women’s health in the United States and internationally. The company’s primary role is to develop and license differentiated therapies that address conditions associated with menopause, contraception, and related gynecologic needs. Through licensing agreements, TherapeuticsMD grants commercial rights to partners such as Mayne Pharma for products including hormone therapy and contraceptive offerings, while retaining economic interests via royalties. Its portfolio is complemented by vitamin and prenatal brands historically developed through its VitaMed business, aimed at obstetric and gynecologic practices. By concentrating on proprietary formulations and lifecycle management rather than large-scale sales infrastructure, TherapeuticsMD, Inc. positions itself as an asset-light participant in the pharmaceutical value chain, contributing specialized products to the broader women’s healthcare market.
1 employees · United States · https://www.therapeuticsmd.com